This site is intended for health professionals only
Tuesday 18 December 2018
Share |

Topic: *** Editor's Pick

December 17, 2018
The study results indicate the need for a personalised approach to delirium in the ICU
A population heath study from the Regenstrief Institute and Indiana University Center for Aging Research has determined that haloperidol, the drug most commonly used to treat delirium in hospital medical and surgical intensive care units (ICUs), did not benefit elective thoracic surgery ICU patients when given prophylactically, with the possible exception of those who have had surgery to remove their oesophagus.
 
The study results indicate the need for a personalised approach to delirium in the ICU.
 
December 12, 2018
The Government has chosen England’s chief pharmacist to look into ‘problematic’ overprescribing in the NHS, it has announced.

The Government has chosen England’s chief pharmacist to look into "problematic" overprescribing in the NHS, it has announced.
 

December 11, 2018
A no-deal Brexit could create disruption over importing and exporting medicines at the Anglo-French border for up to six months, the Government has predicted.

A no-deal Brexit could create disruption over importing and exporting medicines at the Anglo-French border for up to six months, the Government has predicted.
 
In a letter published on 7 December, health and social care secretary Matt Hancock said Britain exiting the European Union without a deal will "significantly" reduce access across the channel for "up to six months".
 

December 11, 2018
The study was a retrospective analysis of all patients with acute ST-segment elevation myocardial infarction treated at Triemli Hospital in Switzerland between 2000 and 2016

Women are being urged to call an ambulance immediately if they have heart attack symptoms, following research showing they wait longer than men to get help. The study has been published in European Heart Journal: Acute Cardiovascular Care, a publication of the European Society of Cardiology (ESC).1

December 10, 2018
Men with inflamed guts are four to five times at risk for prostate cancer and are in need of more careful screening
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
 
This is the first report to show men with inflammatory bowel disease have higher than average PSA (prostate-specific antigen) values, and this group also has a significantly higher risk of potentially dangerous prostate cancer.
 
December 10, 2018
The Joint Cancer Research UK - AstraZeneca Functional Genomics Centre will be a dedicated world-class resource for AstraZeneca and Cancer Research UK’s academics and alliance partners working at all stages of translational research, from target discovery and validation, to assessing novel drug combinations
Cancer Research UK and AstraZeneca have announced that they are opening a new centre in the UK, dedicated to realising the full potential of functional genomics in the discovery and development of new drugs for patients with cancer.
 
This partnership will explore in more detail the function and interaction of genes and proteins in cancer, and apply new genome-altering technologies such as CRISPR, to create sophisticated models of the disease for research.
 
December 7, 2018
Researchers at the Karolinska Institutet in Sweden have published results showing that online cognitive behavioural therapy can be useful in treating gastrointestinal disorders in children when no physical cause can be found

Cognitive behavioural therapy (CBT) online can be useful in treating gastrointestinal disorders in children when no physical cause can be found.

This is the viewpoint of researchers at Karolinska Institutet in Sweden that is described in a new study published in the journal Clinical Gastroenterology and Hepatology.1

December 6, 2018
Observations from a recent Phase II trial support further development of ustekinumab as a new therapy for SLE, and results from Phase III trials are awaited

Development of new treatments for systemic lupus erythematosus (SLE) has been challenging.

Many components of the immune system have been identified as targets for novel therapies, but the majority of the clinical trials have failed. However, many trials are ongoing and some of them have reported promising preliminary results.

December 6, 2018
Delays in taking new cancer drugs through clinical trials and getting them approved for use mean NHS patients are waiting longer to access them, a report by the Institute of Cancer Research (ICR) finds.

NHS patients are waiting longer for new cancer drugs because of delays in taking them through clinical trials and getting them approved for use, a new report has revealed.

The average time from when a cancer drug is patented to approval by NICE increased from 12.7 years between 2000-08 to 14.1 years between 2009-16, The Institute of Cancer Research, London (ICR) found.

December 6, 2018
One-year open-label extension study ongoing, with patients already well treated with ABX464 for a total of 5 to 12 months (induction and maintenance study)
Abivax, a biotechnology company harnessing the immune system to develop treatments for inflammatory/autoimmune diseases, infectious diseases and cancer, has announced that the Data Safety Monitoring Board (DSMB) has recommended continuation of its ongoing 12-month open-label maintenance extension study, ABX464-102, continuing its completed randomised, placebo-controlled Phase IIa induction trial, ABX464-101.
 
December 6, 2018
Research shows 31% of medication administration errors in English and Welsh acute care trusts are due to omitted medicine or ingredient.

Three in 10 drug-related deaths occurring in acute care settings are caused by omission, a study has revealed.
 

December 6, 2018
Leading academics and health data specialists have formed an alliance to boost science and innovation in the UK

The UK’s leading academics and health data specialists have formed an alliance to develop new ways to design and support the medical research of the future, and to improve the care patients receive from the NHS.
 
The UK Health Data Research Alliance will look atthe best ways to design, use, collect, manage and analyse health data in a responsible way for clinical trials, medical research, and innovation.
 

December 4, 2018
The researchers used a next-generation peptide-based immunoassay to subdivide allergenic milk proteins into smaller peptide fragments — called epitopes — and measured the reactivity of the epitopes to a patient’s IgE/IgG4 antibodies
AllerGenis has reported research results in The Journal of Allergy and Clinical Immunology(JACI) that demonstrate the ability to predict, with significant accuracy, milk allergy patients’ outcomes before milk oral immunotherapy treatment (Milk-OIT) is administered, using the company’s novel milk allergy diagnostic assay.  
 
December 3, 2018
An opinion from the CHMP is expected in the second half of 2019

Celltrion has announced that the European Medicines Agency (EMA) has accepted for review of the Extension Marketing Authorisation Application for ‘Remsima SC’, the subcutaneous (SC) version of Remsima®, the autoimmune disease therapeutic antibody biosimilar of infliximab.

December 3, 2018
Faecal calprotectin has a prognostic role for disease course in Crohn's disease and studies have suggested a revision of guidelines to incorporate it as a treatment target
The diagnosis of Crohn’s disease (CD) does not rely on a single gold standard but requires the integration of clinical data with endoscopic, histologic, radiological and biochemical investigations.1
 
December 3, 2018
The study recommends active surveillance to prevent over-treatment, suggesting that 36% of patients with a new diagnosis are candidates for active surveillance, 30% of whom will ultimately have treatment for progression
A new study has confirmed the effectiveness of Prostate-specific Antigen (PSA) screening in reducing prostate cancer mortality.
 
The retrospective cohort study of over 400,000 men, as published in Elsevier’s Urology® journal,1 set out to re-examine the value of PSA screening, to determine the optimal screening interval and the appropriate age groups to be screened. 
 
December 3, 2018
The study explored how different exposures during pregnancy, birth or childhood modulate asthma-related immune responses in children
The prevalence of allergic diseases has increased significantly over the last decades, creating substantial financial and societal burdens. Due to this, researchers are trying to discover new approaches to the prevention and treatment of these diseases. 
 
A new PhD thesis from the University of Eastern Finland shows that there is a link between immune responses and diverse early life exposures, such as obstetric factors, farm dust and air pollution. Some changes in immune responses are visible up until adolescence.
December 3, 2018
An international research team from Italy and France has now uncovered a new molecular player in the development of gluten intolerance
Coeliac disease is a severe autoimmune disorder of the intestine. It occurs when people develop sensitivity to gluten, a substance found in wheat, rye, and barley. An international research team from Italy and France has now uncovered a new molecular player in the development of gluten intolerance.
 
Their discovery, published in The EMBO Journal, suggests potential targets for the development of therapeutic approaches for the disease.
 
November 30, 2018
Researchers exposed lung, ovarian and colon cancer cells, and mouse models, to conditions similar to those in the human body, and investigated how manipulating cell metabolism can make cancer more vulnerable to oncolytic viruses

Restricting the ability of cancer cells to metabolise sugar could make oncolytic viruses more effective at attacking them, suggests a study published in the journal Cancer Research.

Viruses that are trained to attack cancer cells – known as oncolytic viruses – can kill tumours without affecting healthy cells nearby. They normally work by invading the cells, multiplying and destroying the tumour from inside. They are currently being tested in clinical trials.

November 30, 2018
Cancer patients in England have a poorer survival rate than patients in other European countries, according to the Health Foundation.

Cancer patients in England have a poorer survival rate than patients in other European countries, according to the Health Foundation.
 
A report by the charity looked at the progress made since the NHS Cancer Plan in 2000, which aimed to see five-year survival rates for cancer in England compare with the best in Europe by 2010.
 
Delays in diagnosis and treatment
 

November 29, 2018
A survey of people working within pharmaceutical industry within and outside the UK found growing negativity about the impact of Brexit on the UK healthcare sector

The majority of pharmaceutical professionals now say Brexit will have a negative impact on the UK healthcare sector, a survey has revealed.
 
Negative sentiment amongst healthcare professionals about the impact of Brexit on the UK healthcare sector has increased over the last three months, according to data and analytics company GlobalData.

November 29, 2018
CAR-T treatment involves collecting and using a patient’s own immune cells to fight the cancer over a number of weeks.

Children with cancer at Great Ormond Street Hospital in London are this week starting a new therapy treatment tailored to target patients’ specific cancer cells.
 
The CAR-T treatment involves collecting and using a patient’s own immune cells to fight the cancer over a number of weeks. 
 
Royal Manchester Children’s Hospital is also offering the immunotherapy treatment, and Newcastle upon Tyne Hospitals NHS Foundation Trust will join next month.
 

November 29, 2018
The discovery could potentially accelerate early diagnosis, speed up drug discovery and lead to advancements in personalised medicines

A technique to get more information from the blood of cancer patients than previously possible has been developed.

The discovery could potentially accelerate early diagnosis, speed up drug discovery and lead to advancements in personalised medicines. The Cancer Research UK-funded study has been published in Advanced Materials.

November 29, 2018
In the EU, regorafenib is indicated for treatment of adult patients with advanced unresectable hepatocellular carcinoma who have been previously treated with sorafenib
Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Stivarga® (regorafenib) as an option for treating advanced unresectable hepatocellular carcinoma (HCC) in adults who have had Nexavar® (sorafenib) only if patientshave Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.1